
Ferrer, Leti and Oryzon to collaborate in R&D
Catalan Economy
21 Nov 2009
Pharmaceutical companies Ferrer and Leti and biotech firm Oryzon have announced the creation of the Oncochip alliance to further develop cancer research in Catalonia. Madrid-based Ingenasa and Navarra’s CIMA are also to participate in the project.
With a budget of over EUR 20 million, Oncochip will focus on the design of therapies for early diagnosis of ovarian cancer, melanoma and colon cancer. Oryzon specializes in the detection of cancer biomarkers and is already working with Reig Jofré on uterine cancer research.
Ferrer, Leti and Oryzon also plan to create a new partnership next year to develop nanotechnology projects.
Source: Expansión Cataluña 16/11/2009
Related News and Success stories.
-
19 Jun 2025
Mobile World Congress 2025 generated €561 million economic impact to Barcelona
-
11 Jun 2025
Barcelona-based SpliceBio secures a €118 million financing round for advancing in gene therapy
-
11 Jun 2025
Catalonia targets Asian markets with first wine trade mission to China and Taiwan
-
06 Jun 2025
Barcelona chosen as UNESCO's global hub for the sustainable Blue Economy